Ustekinumab demonstrates rapid onset of efficacy in the treatment of moderate-to-severe psoriasis

被引：0
|
作者：
Rich, P. [1 ]
Feldman, S. [2 ]
Vender, R. [3 ]
Ortonne, J. P. [4 ]
Rustin, M. [5 ]
Kunynetz, R. [6 ]
Yeilding, N. [7 ]
Fakharzadeh, S. [8 ]
Li, S. [7 ]
Prinz, J. [9 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR USA
[2] Wake Forest Univ, Baptis Med Ctr, Winston Salem, NC 27109 USA
[3] Dermatrials Res & McMaster Univ, Hamilton, ON, Canada
[4] Hop Archet, Nice, France
[5] Royal Free Hosp, London NW3 2QG, England
[6] Univ Toronto, Barrie, ON, Canada
[7] Centocor Res & Dev Inc, Malvern, PA USA
[8] LLC, Centocor Ortho Biotech Serv, Horsham, PA USA
[9] Univ Munich, Munich, Germany
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P040
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis
    Talamonti, M.
    Galluzzo, M.
    Teoli, M.
    Bavetta, M.
    Chimenti, S.
    Costanzo, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E34 - E34
  • [2] Long-term efficacy of ustekinumab in moderate-to-severe psoriasis
    Kimball, A. B.
    Gordon, K. B.
    Fakharzadeh, S.
    Yeilding, N.
    Szapary, P. O.
    Schenkel, B.
    Guzzo, C.
    Li, S.
    Papp, K. A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04)
  • [3] Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
    Scanlon, James V.
    Exter, Benjamin P.
    Steinberg, Michael
    Jarvis, Courtney I.
    [J]. ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1456 - 1465
  • [4] Efficacy of Ustekinumab in the Treatment of Moderate-Severe Psoriasis
    Jimenez-Puya, R.
    Moreno, J. C.
    [J]. ACTAS DERMO-SIFILIOGRAFICAS, 2012, 103 : 16 - 24
  • [5] Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
    Griffiths, Christopher E. M.
    Strober, Bruce E.
    van de Kerkhof, Peter
    Ho, Vincent
    Fidelus-Gort, Roseanne
    Yeilding, Newman
    Guzzo, Cynthia
    Xia, Yichuan
    Zhou, Bei
    Li, Shu
    Dooley, Lisa T.
    Goldstein, Neil H.
    Menter, Alan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (02): : 118 - 128
  • [6] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [7] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    [J]. DERMATOLOGIC THERAPY, 2017, 30 (05)
  • [8] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [9] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Prieto-Perez, Rocio
    Llamas-Velasco, Mar
    Cabaleiro, Teresa
    Solano-Lopez, Guillermo
    Marquez, Beatriz
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Dauden, Esteban
    Abad-Santos, Francisco
    [J]. PHARMACOGENOMICS, 2017, 18 (02) : 157 - 164
  • [10] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Dauden, E.
    Prieto-Perez, R.
    Llamas-Velasco, M.
    Cabaleiro, T.
    Abad-Santos, F.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
12345